<p>NBT Bank N A NY 在最近向證券交易委員會（SEC）披露的文件中表示，在第二季度減少了對百時美施貴寶公司（NYSE:BMY - 免費報告）21.4% 的持股。該公司在季度內出售了 16,600 股後，持有 60,930 股生物製藥公司的股票。在最近的報告期結束時，NBT Bank N A NY 在百時美施貴寶的持股價值為 2,820,000 美元。</p>
<p>獲取 <strong>百時美施貴寶</strong> 的提醒：</p>
<ul>
<li>不要被反彈所迷惑：市場風暴尚未結束</li>
</ul>
<p>其他幾家對沖基金最近也增加或減少了對 BMY 的持股。先鋒集團（Vanguard Group Inc.）在第一季度將其在百時美施貴寶的持股增加了 0.8%。先鋒集團目前持有 191,403,004 股生物製藥公司的股票，價值為 11,673,669,000 美元，此前在該期間又購買了 1,458,488 股。查爾斯·施瓦布投資管理公司（Charles Schwab Investment Management Inc.）在第一季度將其在百時美施貴寶的持股增加了 0.5%。查爾斯·施瓦布投資管理公司目前持有 60,606,905 股生物製藥公司的股票，價值為 3,696,415,000 美元，此前在該期間又收購了 306,430 股。紐約梅隆銀行（Bank of New York Mellon Corp）在第一季度將其在百時美施貴寶的持股增加了 8.6%。紐約梅隆銀行目前持有 26,865,073 股生物製藥公司的股票，價值為 1,638,501,000 美元，此前在該期間又收購了 2,131,205 股。北方信託公司（Northern Trust Corp）在第一季度將其在百時美施貴寶的持股增加了 5.3%。北方信託公司目前持有 25,974,504 股生物製藥公司的股票，價值為 1,584,185,000 美元，此前在該期間又購買了 1,316,144 股。最後，威靈頓管理集團（Wellington Management Group LLP）在第一季度將其在百時美施貴寶的持股增加了 297.0%。威靈頓管理集團目前持有 23,728,443 股生物製藥公司的股票，價值為 1,447,198,000 美元，此前在該期間又購買了 17,750,938 股。機構投資者和對沖基金持有該公司 76.41% 的股票。</p>
<h2>百時美施貴寶股價下跌 1.1%</h2>
<p>BMY 週三開盤價為 44.63 美元。該公司的債務與股本比率為 2.54，流動比率為 1.21，速動比率為 1.11。該公司的市值為 908.4 億美元，市盈率為 18.00，市盈增長比率為 2.31，貝塔值為 0.33。該公司的 50 日簡單移動平均線為 46.27 美元，200 日簡單移動平均線為 48.36 美元。百時美施貴寶公司的 52 周最低價為 42.96 美元，52 周最高價為 63.33 美元。</p>
<ul>
<li>MarketBeat 週迴顧 – 02/03 - 02/07</li>
</ul>
<p>百時美施貴寶（NYSE:BMY - 獲取免費報告）最近在 7 月 31 日（星期四）發佈了季度財報。該生物製藥公司報告本季度每股收益為 1.46 美元，超出分析師一致預期的 1.07 美元，超出幅度為 0.39 美元。百時美施貴寶的淨利潤率為 10.58%，股本回報率為 80.04%。該公司本季度的收入為 122.7 億美元，而一致預期為 113.2 億美元。在去年同期，該公司每股收益為 2.07 美元。百時美施貴寶本季度的收入較去年同期增長了 0.6%。百時美施貴寶已將其 2025 財年的指引設定為每股收益 6.350-6.650 美元。平均而言，賣方分析師預計百時美施貴寶公司今年將發佈每股收益 6.74 美元。</p>
<h2>百時美施貴寶宣佈分紅</h2>
<p>該公司最近還宣佈了一項季度分紅，將於 11 月 3 日（星期一）支付。10 月 3 日（星期五）登記在冊的股東將獲得 0.62 美元的分紅。這相當於每年 2.48 美元的分紅，收益率為 5.6%。該分紅的除息日為 10 月 3 日（星期五）。百時美施貴寶的分紅支付比率目前為 100.00%。</p>
<h2>內部人員買賣情況</h2>
<ul>
<li>百時美施貴寶的疲軟指引可能創造了機會</li>
</ul>
<p>在其他消息中，執行副總裁 David V. Elkins 在 9 月 2 日（星期二）出售了 56,000 股該股票。股票以平均價格 47.33 美元出售，總交易額為 2,650,480.00 美元。出售完成後，該執行副總裁持有 167,379 股公司股票，價值為 7,922,048.07 美元。這代表其持股減少了 25.07%。該交易已在向證券交易委員會的法律文件中披露，文件可通過此鏈接獲取。內部人士持有公司 0.07% 的股票。</p>
<h2>華爾街分析師觀點</h2>
<p>幾家研究公司最近對 BMY 發佈了報告。大和資本市場（Daiwa Capital Markets）將百時美施貴寶的股票評級從 “跑贏大盤” 下調至 “中性”，並設定了 42.00 美元的目標價。在 8 月 5 日（星期二）的報告中，大和美國（Daiwa America）將百時美施貴寶的股票評級從 “強烈買入” 下調至 “持有”。摩根士丹利（Morgan Stanley）在 7 月 31 日（星期四）的研究報告中重申了對百時美施貴寶的 “持有” 評級。花旗集團（Citigroup）在 8 月 1 日（星期五）的研究報告中將百時美施貴寶的目標價從 51.00 美元下調至 47.00 美元，並對該股票設定了 “中性” 評級。最後，Dbs Bank 在 10 月 2 日（星期四）的研究報告中將百時美施貴寶的股票評級上調至 “適度買入”。一位股票研究分析師對該股票給予了 “強烈買入” 評級，五位分析師給予 “買入” 評級，十五位分析師對該公司的股票給予 “持有” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “持有”，平均目標價為 57.14 美元。</p>
<p><strong>查看我們關於 BMY 的最新報告</strong></p>
<h2>百時美施貴寶簡介</h2>
<p>（免費報告）</p>
<p>百時美施貴寶公司在全球範圍內發現、開發、許可、製造、營銷、分銷和銷售生物製藥產品。它提供針對血液學、腫瘤學、心血管、免疫學、纖維化和神經科學疾病的產品。公司的產品包括 Eliquis，用於降低非瓣膜性房顫患者中風/全身栓塞的風險，以及治療深靜脈血栓/DVT/肺栓塞/PE；Opdivo，用於多種抗癌適應症，包括膀胱癌、血液癌、結直腸癌、頭頸癌、腎細胞癌、肝細胞癌、肺癌、黑色素瘤、胸膜間皮瘤、胃癌和食道癌；Pomalyst/Imnovid 用於多發性骨髓瘤；Orencia 用於活動性類風濕關節炎和銀屑病關節炎；Sprycel 用於治療費城染色體陽性慢性髓性白血病。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們認為比百時美施貴寶更好的股票</li>
<li>投資者最重要的沃倫·巴菲特股票：他自己的股票</li>
<li>EA 的 550 億美元交易引發遊戲行業的震盪</li>
<li>什麼是股票市場指數，如何使用它們？</li>
<li>這些是第三季度盈利增長的三個熱門行業</li>
<li>國會股票交易跟蹤</li>
<li>AMD 可能會在此基礎上翻倍——得益於其與 OpenAI 的重磅交易</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在百時美施貴寶嗎？</h2>
<p>在你考慮百時美施貴寶之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而百時美施貴寶並不在名單上。</p>
<p>雖然百時美施貴寶目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

百時美施貴寶

<p>NBT Bank N A NY 在第二季度減少了對百時美施貴寶公司的持股比例，下降了 21.4%，目前持有 60,930 股，價值 282 萬美元。其他對沖基金，包括先鋒集團和查爾斯·施瓦布，也調整了他們的持股。百時美施貴寶的股票開盤價為 44.63 美元，市值為 908.4 億美元。該公司報告第二季度每股收益為 1.46 美元，超出預期，並宣佈季度股息為 0.62 美元，收益率為 5.6%。內部人士出售股票的情況被注意到，執行副總裁 David V. Elkins 最近出售了 56,000 股</p>

<p>NBT Bank N A NY lessened its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 21.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 60,930 shares of the biopharmaceutical company's stock after selling 16,600 shares during the quarter. NBT Bank N A NY's holdings in Bristol Myers Squibb were worth $2,820,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>NBT Bank N A NY 在最近向證券交易委員會（SEC）披露的文件中表示，在第二季度減少了對百時美施貴寶公司（NYSE:BMY - 免費報告）21.4% 的持股。該公司在季度內出售了 16,600 股後，持有 60,930 股生物製藥公司的股票。在最近的報告期結束時，NBT Bank N A NY 在百時美施貴寶的持股價值為 2,820,000 美元。</p>
</div><p>Get <strong>Bristol Myers Squibb</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>百時美施貴寶</strong> 的提醒：</p>
</div><ul>
<li>Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet</li>
</ul>
<div class="lb-trans"><ul>
<li>不要被反彈所迷惑：市場風暴尚未結束</li>
</ul>
</div><p>Several other hedge funds have also recently added to or reduced their stakes in BMY. Vanguard Group Inc. boosted its stake in shares of Bristol Myers Squibb by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 191,403,004 shares of the biopharmaceutical company's stock valued at $11,673,669,000 after buying an additional 1,458,488 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Bristol Myers Squibb by 0.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 60,606,905 shares of the biopharmaceutical company's stock worth $3,696,415,000 after acquiring an additional 306,430 shares during the period. Bank of New York Mellon Corp raised its holdings in Bristol Myers Squibb by 8.6% in the 1st quarter. Bank of New York Mellon Corp now owns 26,865,073 shares of the biopharmaceutical company's stock worth $1,638,501,000 after acquiring an additional 2,131,205 shares during the period. Northern Trust Corp increased its holdings in shares of Bristol Myers Squibb by 5.3% during the 1st quarter. Northern Trust Corp now owns 25,974,504 shares of the biopharmaceutical company's stock worth $1,584,185,000 after purchasing an additional 1,316,144 shares during the period. Finally, Wellington Management Group LLP increased its holdings in shares of Bristol Myers Squibb by 297.0% during the 1st quarter. Wellington Management Group LLP now owns 23,728,443 shares of the biopharmaceutical company's stock worth $1,447,198,000 after purchasing an additional 17,750,938 shares during the period. Institutional investors and hedge funds own 76.41% of the company's stock.</p>
<div class="lb-trans"><p>其他幾家對沖基金最近也增加或減少了對 BMY 的持股。先鋒集團（Vanguard Group Inc.）在第一季度將其在百時美施貴寶的持股增加了 0.8%。先鋒集團目前持有 191,403,004 股生物製藥公司的股票，價值為 11,673,669,000 美元，此前在該期間又購買了 1,458,488 股。查爾斯·施瓦布投資管理公司（Charles Schwab Investment Management Inc.）在第一季度將其在百時美施貴寶的持股增加了 0.5%。查爾斯·施瓦布投資管理公司目前持有 60,606,905 股生物製藥公司的股票，價值為 3,696,415,000 美元，此前在該期間又收購了 306,430 股。紐約梅隆銀行（Bank of New York Mellon Corp）在第一季度將其在百時美施貴寶的持股增加了 8.6%。紐約梅隆銀行目前持有 26,865,073 股生物製藥公司的股票，價值為 1,638,501,000 美元，此前在該期間又收購了 2,131,205 股。北方信託公司（Northern Trust Corp）在第一季度將其在百時美施貴寶的持股增加了 5.3%。北方信託公司目前持有 25,974,504 股生物製藥公司的股票，價值為 1,584,185,000 美元，此前在該期間又購買了 1,316,144 股。最後，威靈頓管理集團（Wellington Management Group LLP）在第一季度將其在百時美施貴寶的持股增加了 297.0%。威靈頓管理集團目前持有 23,728,443 股生物製藥公司的股票，價值為 1,447,198,000 美元，此前在該期間又購買了 17,750,938 股。機構投資者和對沖基金持有該公司 76.41% 的股票。</p>
</div><h2>Bristol Myers Squibb Trading Down 1.1%</h2>
<div class="lb-trans"><h2>百時美施貴寶股價下跌 1.1%</h2>
</div><p>BMY opened at $44.63 on Wednesday. The company has a debt-to-equity ratio of 2.54, a current ratio of 1.21 and a quick ratio of 1.11. The company has a market cap of $90.84 billion, a price-to-earnings ratio of 18.00, a price-to-earnings-growth ratio of 2.31 and a beta of 0.33. The firm has a 50 day simple moving average of $46.27 and a 200 day simple moving average of $48.36. Bristol Myers Squibb Company has a fifty-two week low of $42.96 and a fifty-two week high of $63.33.</p>
<div class="lb-trans"><p>BMY 週三開盤價為 44.63 美元。該公司的債務與股本比率為 2.54，流動比率為 1.21，速動比率為 1.11。該公司的市值為 908.4 億美元，市盈率為 18.00，市盈增長比率為 2.31，貝塔值為 0.33。該公司的 50 日簡單移動平均線為 46.27 美元，200 日簡單移動平均線為 48.36 美元。百時美施貴寶公司的 52 周最低價為 42.96 美元，52 周最高價為 63.33 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 02/03 - 02/07</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週迴顧 – 02/03 - 02/07</li>
</ul>
</div><p>Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. During the same period in the previous year, the firm posted $2.07 earnings per share. Bristol Myers Squibb's revenue for the quarter was up .6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.</p>
<div class="lb-trans"><p>百時美施貴寶（NYSE:BMY - 獲取免費報告）最近在 7 月 31 日（星期四）發佈了季度財報。該生物製藥公司報告本季度每股收益為 1.46 美元，超出分析師一致預期的 1.07 美元，超出幅度為 0.39 美元。百時美施貴寶的淨利潤率為 10.58%，股本回報率為 80.04%。該公司本季度的收入為 122.7 億美元，而一致預期為 113.2 億美元。在去年同期，該公司每股收益為 2.07 美元。百時美施貴寶本季度的收入較去年同期增長了 0.6%。百時美施貴寶已將其 2025 財年的指引設定為每股收益 6.350-6.650 美元。平均而言，賣方分析師預計百時美施貴寶公司今年將發佈每股收益 6.74 美元。</p>
</div><h2>Bristol Myers Squibb Announces Dividend</h2>
<div class="lb-trans"><h2>百時美施貴寶宣佈分紅</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be paid a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 5.6%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb's dividend payout ratio is presently 100.00%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度分紅，將於 11 月 3 日（星期一）支付。10 月 3 日（星期五）登記在冊的股東將獲得 0.62 美元的分紅。這相當於每年 2.48 美元的分紅，收益率為 5.6%。該分紅的除息日為 10 月 3 日（星期五）。百時美施貴寶的分紅支付比率目前為 100.00%。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人員買賣情況</h2>
</div><ul>
<li>Weak Guidance from Bristol-Myers Could Be Creating an Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>百時美施貴寶的疲軟指引可能創造了機會</li>
</ul>
</div><p>In other news, EVP David V. Elkins sold 56,000 shares of the stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the completion of the sale, the executive vice president owned 167,379 shares of the company's stock, valued at $7,922,048.07. This represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Insiders own 0.07% of the company's stock.</p>
<div class="lb-trans"><p>在其他消息中，執行副總裁 David V. Elkins 在 9 月 2 日（星期二）出售了 56,000 股該股票。股票以平均價格 47.33 美元出售，總交易額為 2,650,480.00 美元。出售完成後，該執行副總裁持有 167,379 股公司股票，價值為 7,922,048.07 美元。這代表其持股減少了 25.07%。該交易已在向證券交易委員會的法律文件中披露，文件可通過此鏈接獲取。內部人士持有公司 0.07% 的股票。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Several research firms have recently issued reports on BMY. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and set a $42.00 price objective on the stock. in a report on Tuesday, August 5th. Daiwa America lowered shares of Bristol Myers Squibb from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, August 5th. Morgan Stanley reiterated a &#34;hold&#34; rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Citigroup decreased their target price on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a &#34;neutral&#34; rating on the stock in a research report on Friday, August 1st. Finally, Dbs Bank upgraded shares of Bristol Myers Squibb to a &#34;moderate buy&#34; rating in a research report on Thursday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and fifteen have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of &#34;Hold&#34; and an average price target of $57.14.</p>
<div class="lb-trans"><p>幾家研究公司最近對 BMY 發佈了報告。大和資本市場（Daiwa Capital Markets）將百時美施貴寶的股票評級從 “跑贏大盤” 下調至 “中性”，並設定了 42.00 美元的目標價。在 8 月 5 日（星期二）的報告中，大和美國（Daiwa America）將百時美施貴寶的股票評級從 “強烈買入” 下調至 “持有”。摩根士丹利（Morgan Stanley）在 7 月 31 日（星期四）的研究報告中重申了對百時美施貴寶的 “持有” 評級。花旗集團（Citigroup）在 8 月 1 日（星期五）的研究報告中將百時美施貴寶的目標價從 51.00 美元下調至 47.00 美元，並對該股票設定了 “中性” 評級。最後，Dbs Bank 在 10 月 2 日（星期四）的研究報告中將百時美施貴寶的股票評級上調至 “適度買入”。一位股票研究分析師對該股票給予了 “強烈買入” 評級，五位分析師給予 “買入” 評級，十五位分析師對該公司的股票給予 “持有” 評級。根據 MarketBeat.com 的數據，該股票目前的共識評級為 “持有”，平均目標價為 57.14 美元。</p>
</div><p><strong>View Our Latest Report on BMY</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 BMY 的最新報告</strong></p>
</div><h2>Bristol Myers Squibb Profile</h2>
<div class="lb-trans"><h2>百時美施貴寶簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.</p>
<div class="lb-trans"><p>百時美施貴寶公司在全球範圍內發現、開發、許可、製造、營銷、分銷和銷售生物製藥產品。它提供針對血液學、腫瘤學、心血管、免疫學、纖維化和神經科學疾病的產品。公司的產品包括 Eliquis，用於降低非瓣膜性房顫患者中風/全身栓塞的風險，以及治療深靜脈血栓/DVT/肺栓塞/PE；Opdivo，用於多種抗癌適應症，包括膀胱癌、血液癌、結直腸癌、頭頸癌、腎細胞癌、肝細胞癌、肺癌、黑色素瘤、胸膜間皮瘤、胃癌和食道癌；Pomalyst/Imnovid 用於多發性骨髓瘤；Orencia 用於活動性類風濕關節炎和銀屑病關節炎；Sprycel 用於治療費城染色體陽性慢性髓性白血病。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Bristol Myers Squibb</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector</li>
<li>What is a Stock Market Index and How Do You Use Them?</li>
<li>These Are the 3 Hottest Sectors for Q3 Earnings Growth</li>
<li>Following Congress Stock Trades</li>
<li>AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們認為比百時美施貴寶更好的股票</li>
<li>投資者最重要的沃倫·巴菲特股票：他自己的股票</li>
<li>EA 的 550 億美元交易引發遊戲行業的震盪</li>
<li>什麼是股票市場指數，如何使用它們？</li>
<li>這些是第三季度盈利增長的三個熱門行業</li>
<li>國會股票交易跟蹤</li>
<li>AMD 可能會在此基礎上翻倍——得益於其與 OpenAI 的重磅交易</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJNWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=BMY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Bristol Myers Squibb Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在百時美施貴寶嗎？</h2>
</div><p>Before you consider Bristol Myers Squibb, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮百時美施貴寶之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而百時美施貴寶並不在名單上。</p>
</div><p>While Bristol Myers Squibb currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然百時美施貴寶目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

NBT Bank N A NY 減少了其在百時美施貴寶公司 $BMY 的持股